TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is among the Most Volatile Stocks.

On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook. TD Cowen said that community adoption, new indications, pharma guidelines, EMR integrations, and a shift to blood-based testing were major driving factors.

On February 6, 2026, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and increased its price target from $21 to $22, following Q4 earnings. BTIG describes the company as a leading growth story in specialty labs.

On February 6, 2026, JPMorgan boosted Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price objective from $20 to $21 while retaining an Overweight rating, citing the Q4 report as strong. The corporation anticipates FY26 MRD business revenue of $255 million to $265 million, with total operating expenses, including cost of revenue, ranging from $350 million to $360 million.

TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)

Mila Supinskaya Glashchenko/Shutterstock.com

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) develops an immune medicine platform. The company provides immunoSEQ, clonoSEQ, cellular treatment, and vaccinations.

While we acknowledge the potential of ADPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ADPT and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026.

Disclosure: None.